Skip to main content

Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder.

Publication ,  Journal Article
Sun, JM; Dawson, G; Franz, L; Howard, J; McLaughlin, C; Kistler, B; Waters-Pick, B; Meadows, N; Troy, J; Kurtzberg, J
Published in: Stem Cells Transl Med
October 2020

Ongoing neuroinflammation may contribute to symptoms of autism spectrum disorder (ASD) in at least a portion of affected individuals. Mesenchymal stromal cells (MSCs) have demonstrated the capacity to modulate neuroinflammation, but safety and feasibility of MSC administration in children with ASD have not been well established. In this open-label, phase I study, 12 children with ASD between 4 and 9 years of age were treated with intravenous (IV) infusions of human cord tissue mesenchymal stromal cells (hCT-MSCs), a third-party MSC product manufactured from unrelated donor umbilical cord tissue. Children received one, two, or three doses of 2 × 106 cells per kilogram at 2-month intervals. Clinical and laboratory evaluations were performed in person at baseline and 6 months and remotely at 12 months after the final infusion. Aside from agitation during the IV placement and infusion in some participants, hCT-MSCs were well tolerated. Five participants developed new class I anti-human leukocyte antigen (HLA) antibodies, associated with a specific lot of hCT-MSCs or with a partial HLA match between donor and recipient. These antibodies were clinically silent and not associated with any clinical manifestations to date. Six of 12 participants demonstrated improvement in at least two ASD-specific measures. Manufacturing and administration of hCT-MSCs appear to be safe and feasible in young children with ASD. Efficacy will be evaluated in a subsequent phase II randomized, placebo-controlled clinical trial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Stem Cells Transl Med

DOI

EISSN

2157-6580

Publication Date

October 2020

Volume

9

Issue

10

Start / End Page

1137 / 1146

Location

England

Related Subject Headings

  • Umbilical Cord
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Autism Spectrum Disorder
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sun, J. M., Dawson, G., Franz, L., Howard, J., McLaughlin, C., Kistler, B., … Kurtzberg, J. (2020). Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med, 9(10), 1137–1146. https://doi.org/10.1002/sctm.19-0434
Sun, Jessica M., Geraldine Dawson, Lauren Franz, Jill Howard, Colleen McLaughlin, Bethany Kistler, Barbara Waters-Pick, Norin Meadows, Jesse Troy, and Joanne Kurtzberg. “Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder.Stem Cells Transl Med 9, no. 10 (October 2020): 1137–46. https://doi.org/10.1002/sctm.19-0434.
Sun JM, Dawson G, Franz L, Howard J, McLaughlin C, Kistler B, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020 Oct;9(10):1137–46.
Sun, Jessica M., et al. “Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder.Stem Cells Transl Med, vol. 9, no. 10, Oct. 2020, pp. 1137–46. Pubmed, doi:10.1002/sctm.19-0434.
Sun JM, Dawson G, Franz L, Howard J, McLaughlin C, Kistler B, Waters-Pick B, Meadows N, Troy J, Kurtzberg J. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020 Oct;9(10):1137–1146.

Published In

Stem Cells Transl Med

DOI

EISSN

2157-6580

Publication Date

October 2020

Volume

9

Issue

10

Start / End Page

1137 / 1146

Location

England

Related Subject Headings

  • Umbilical Cord
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Humans
  • Female
  • Child, Preschool
  • Child
  • Autism Spectrum Disorder
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology